

CD45	97.6	172
CD14	6.8	
CD3	13	
CD19	15	
CD56	3.8	
CD4-PE	95	
CD25	1.7	
CD45RO	99	

CD16	1.8	31
CD32	63	163
CD64	4	12

CD1a	31	216
CD1c	58	505
CD83	9	18

HLA-DR	99	266
HLA-I	99.6	582
CD40	98	991
CD80	78	64
CD86	99	744

IgG1-FITC	6.7	11
IgG1-PE	20	(16) 55
IgG1-Cy5	19	(29) 50
IgG2a-FITC	5.3	19
IgG1 i	1.6	75
IgG2a i	3.8	21
IgG2b i	3.2	15

IN THE CLAIMS:

Amend claim 44 as follows:

--44. (four times amended) Monocyte-derived antigen-presenting cells (MD-APCs) having been produced by

H2 differentiating blood monocytes in vitro, in the presence of lymphocytes, GM-CSF and at least one ligand having a receptor on the surface of monocytes, said MD-APCs having, when compared with monocyte derived macrophages prepared in the presence of GM-CSF only, higher phagocytic properties of formalin fixed yeast and higher ability for stimulation of allogenic T lymphocytes.--

Cancel claim 45. ✓

Amend claim 50 as follows:

H3 --50. (twice amended) The monocyte-derived antigen-presenting cells of claim 44, wherein said monocyte-derived antigen-presenting cells present adherent properties as determined by MD-APCs culture for 2 hours in culture medium of one of I.M.D.M. and R.P.M.I. on plastic flasks and the percentage of adherent cells is quantified by microscopic analysis.--

Amend claim 54 as follows:

H4 --54. (twice amended) The monocyte-derived antigen-presenting cells of claim 47, wherein said monocyte-derived antigen-presenting cells present adherent properties as determined by MD-APCs culture for 2 hours in a culture medium of one of I.M.D.M. and R.P.M.I.--

Amend claim 55 as follows:

--55. (thrice amended) Monocyte-derived antigen-presenting cells (MD-APCs) which present the following properties:

(a) the presence on the MD-APC cell surface of surface antigens CD80 and CD86; and

H5 (b) the presence on the MD-APC cell surface of surface antigen CD14,

said MD-APCs have been produced by differentiating blood monocytes in vitro, in the presence of lymphocytes, GM-CSF and at least one ligand having a receptor on the surface of monocytes, said MD-APCs having, when compared with monocyte derived macrophages prepared in the presence of GM-CSF only, higher phagocytic properties of formalin fixed yeast and higher ability for stimulation of allogenic T lymphocytes.--

✓  
Cancel claim 58.

Amend claim 60 as follows:

H6 --60. (amended) The monocyte-derived antigen-presenting cells of claim 55, wherein said monocyte-derived antigen-presenting cells are substantially devoid of the surface antigens CD1a and CD1c.--